Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Lonza Group AG
  6. News
  7. Summary
    LONN   CH0013841017


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Leucid Bio and Lonza Enter Strategic Collaboration to Leverage the Cocoon? Platform for Automated Manufacturing of Personalised CAR T-Cells

12/02/2021 | 03:30am EST

Leucid Bio announced that it has entered a strategic collaboration with Lonza to utilize Lonza's Cocoon? Platform for the Company's forthcoming Phase I clinical trial, through to commercial manufacturing. Under the terms of the collaboration, Leucid will utilise Lonza as its preferred manufacturer, aiming to deliver high quality cell therapies quickly and cost-effectively to patients in a decentralized manufacturing model. Leucid is, in turn, one of Lonza's preferred collaborators on the Cocoon? Platform, and both companies will work together to optimise and streamline the manufacturing process for Leucid's CAR-T therapies. As a preferred collaborator, Leucid will have early access to new Cocoon? Platform technologies. Founded to translate 20 years of pioneering CAR-T research led by Dr. John Maher at King's College London, Leucid has developed a proprietary engine that builds upon Dr. Maher's novel parallel CAR-T model which positions these molecules in a more natural biological configuration. The Company's technology confers properties on the CART-cells that enable them to consistently outperform previous generations of CAR-T therapies in pre-clinical studies. As a result, this leads to enhanced T-cell potency and persistent long-term response with reduced toxicity. CAR T-cell therapy is a revolutionary technology in which the patient's own immune cells are reprogrammed so they can recognise and destroy cancer cells. This has proven to be a powerful therapy for refractory blood cancers, but has not yet been very effective for the treatment of solid tumours. Leucid's LEU-011 programme is a NKG2D-targeted CAR T-cell therapy in pre-clinical development for the treatment of solid tumours and haematological malignancies. The NKG2D receptor is an activating immune receptor that triggers cell death upon recognition of human NKG2D ligands expressed on transformed, infected or damaged cells. LEU-011 has potential for the treatment of multiple cancer types as NKG2D ligands are expressed on more than 80% of human tumour cells.

ę S&P Capital IQ 2021
All news about LONZA GROUP AG
01/19LONZA : Drug Product Services Participates in the RealHOPE Project to Assess and Improve P..
01/18Lonza Signs Biologics Development Deal With Forbion, BioGeneration Ventures
01/18LONZA : Forbion, and BioGeneration Ventures Extend Collaboration to Add Development and Ma..
01/18LONZA : Launches bYlok Technology for the Discovery and Design of Bispecific Antibodies
01/06AlphaValue/Baader Europe Lowers Price Target on Lonza Group
01/03AlphaValue/Baader Europe Lowers Price Target on Lonza Group
2021AlphaValue/Baader Europe Lowers Price Target on Lonza Group
2021Moderna could be ready to develop Omicron booster in weeks - CEO
2021Lonza and Agilent Announce Strategic Collaboration to Integrate New Analytical Technolo..
2021LONZA : and Agilent Announce Strategic Collaboration to Integrate New Analytical Technolog..
More news
Analyst Recommendations on LONZA GROUP AG
More recommendations
Sales 2021 5 188 M 5 653 M 5 653 M
Net income 2021 705 M 769 M 769 M
Net cash 2021 504 M 549 M 549 M
P/E ratio 2021 64,8x
Yield 2021 0,47%
Capitalization 48 819 M 53 315 M 53 203 M
EV / Sales 2021 9,31x
EV / Sales 2022 8,22x
Nbr of Employees 14 405
Free-Float 99,7%
Duration : Period :
Lonza Group AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends LONZA GROUP AG
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 23
Last Close Price 657,20 CHF
Average target price 798,44 CHF
Spread / Average Target 21,5%
EPS Revisions
Managers and Directors
Pierre-Alain Ruffieux Chief Executive Officer
Philippe Deecke Chief Financial Officer
Albert M. Baehny Chairman
Werner J. Bauer Independent Director
Barbara May Richmond No-Executive Independent Director
Sector and Competitors
1st jan.Capi. (M$)
LONZA GROUP AG-14.10%53 088
MODERNA, INC.-31.46%70 577
IQVIA HOLDINGS INC.-14.84%45 903
SEAGEN INC.-14.26%24 238
CELLTRION, INC.-16.67%19 573